HGH Fragment 176-191 Dosage Guide

HGH Fragment 176-191 is a synthetic peptide consisting of the C-terminal 16 amino acids of human growth hormone (positions 176–191). It was originally isolated by researchers investigating which region of the GH molecule was responsible for its fat-loss effects. The answer was this specific tail-end fragment — it retains the lipolytic (fat-burning) activity of full GH while completely lacking the growth-promoting, IGF-1-elevating, and glucose-disrupting effects.

HGH Fragment 176-191 works through a GH-receptor-independent pathway. It stimulates lipolysis (the breakdown of stored fat into free fatty acids) and inhibits lipogenesis (the formation of new fat). Because it does not bind the GH receptor, it does not raise IGF-1, does not affect blood glucose or insulin sensitivity, does not cause water retention, and does not promote cellular proliferation. It is purely fat-specific. This fragment is also the parent compound of AOD-9604, which is an acetylated, more metabolically stable version with a tyrosine residue added at the C-terminus.

Use our Peptide Dosage to calculate your exact dose based on vial size and concentration.

For a complete overview of its mechanism and research, see our full HGH Fragment 176-191 profile. New to peptides? Start with the Beginner's Guide to Peptides.

HGH Fragment 176-191 is administered exclusively by subcutaneous injection in a fasted state. Oral dosing is not viable for the unmodified fragment (unlike AOD-9604, which has been studied orally). The tables below summarize the most commonly used protocols.

Dosage by Experience Level

Dosing Timing

HGH Fragment 176-191's mechanism is singular — fat mobilization — but the optimal protocol varies depending on the specific fat-loss goal and context.

General Fat Loss

The standard protocol for users seeking moderate, steady fat loss over 8–12 weeks. Suitable for individuals with a moderate caloric deficit and regular exercise.

• Dose: 250 mcg per injection (SubQ)
• Frequency: Twice daily fasted (AM + PM)
• Duration: 8–12 weeks
• Caloric deficit: 300–500 kcal/day recommended

Stubborn Fat Targeting

For users focused on resistant fat deposits (lower abdomen, love handles, lower back). Higher dosing and strict fasting compliance are critical. Some users inject near the stubborn area, though localized fat mobilization from site-specific injection is not confirmed in controlled studies.

• Dose: 250–500 mcg per injection (SubQ)
• Frequency: Twice daily fasted (AM + PM)
• Injection site: Near stubborn fat area (anecdotal preference) or standard abdominal
• Duration: 10–12 weeks minimum

Cutting Phase (Bodybuilding)

Used during dedicated cutting phases to accelerate fat loss while preserving muscle mass (through training and diet, not through the fragment itself). Often stacked with GH secretagogues for muscle preservation during the deficit.

• Dose: 500 mcg per injection (SubQ)
• Frequency: Twice daily fasted (AM + PM)
• Duration: 8–12 weeks (aligned with cutting phase)
• Stack consideration: Ipamorelin or CJC-1295 for GH support during deficit

Metabolic Health & Visceral Fat

For users primarily concerned with visceral (organ-surrounding) fat reduction and metabolic health improvement. The fragment's lack of glucose or insulin effects makes it suitable for individuals who want fat loss without metabolic disruption.

• Dose: 250 mcg per injection (SubQ)
• Frequency: Twice daily fasted (AM + PM)
• Duration: 8–12 weeks
• Note: Does not affect glucose, insulin, or lipid panels directly — fat loss may indirectly improve metabolic markers

HGH Fragment 176-191 is administered exclusively by subcutaneous (SubQ) injection. It is not effective orally (unlike AOD-9604) and intramuscular injection is not standard for this peptide.

Subcutaneous (SubQ) Injection — Step by Step

Injection Site Notes

• Abdomen is standard: Most users inject into abdominal subcutaneous fat. This is convenient, easy to pinch, and allows consistent dosing.
• Site-specific fat loss is debated: Some users inject near stubborn fat deposits (love handles, lower abdomen) believing it enhances local fat mobilization. This is anecdotal — no controlled studies confirm localized effects from injection site selection.
• Rotate injection sites: Alternate between left and right sides of the abdomen or between abdomen and hip to minimize injection site irritation.

Reconstitution & Storage

• Reconstitute with bacteriostatic water — direct the stream down the glass wall of the vial; never squirt onto the powder. Swirl gently; never shake.
• Reconstituted vials: Refrigerate at 2–8°C; use within 21–28 days
• Unreconstituted vials: Refrigerate for best shelf life; room temperature acceptable short-term
• Do not freeze reconstituted peptide — ice crystal formation can damage the short peptide chain
• Protect from light and heat — store in box or wrapped in foil, away from direct sunlight

For a detailed visual walkthrough, see our Reconstitution Guide.

HGH Fragment 176-191 is frequently combined with other peptides to address fat loss from multiple angles or to add benefits the fragment cannot provide on its own (muscle preservation, GH elevation, metabolic optimization).

HGH Fragment 176-191 + AOD-9604 — Dual Fragment Protocol

A debated stack since both compounds target the same lipolytic pathway. AOD-9604 is the acetylated, more stable version of the fragment. Some users combine them for extended coverage (AOD-9604's longer half-life + the fragment's acute pulse). Others consider this redundant. If choosing one, AOD-9604 has more clinical data; if stacking, keep combined doses moderate.

HGH Fragment 176-191 + Ipamorelin — Fat Loss + GH Recovery

Pairs the fragment's targeted fat loss with Ipamorelin's clean GH pulse. Ipamorelin provides the benefits the fragment cannot — improved sleep, recovery, collagen synthesis, and mild anabolic support. The two mechanisms are complementary since the fragment does not work through the GH receptor.

HGH Fragment 176-191 + 5-Amino-1MQ — Metabolic Optimization

5-Amino-1MQ is an NNMT inhibitor that boosts NAD+ levels and enhances metabolic rate. Combined with the fragment's lipolytic action, this stack attacks fat loss from two distinct metabolic pathways — direct fat mobilization plus enhanced cellular energy expenditure.

HGH Fragment 176-191 + CJC-1295/Ipamorelin — Comprehensive Recomp

The most comprehensive stack for users who want fat loss, muscle preservation, and systemic GH benefits. CJC-1295 (DAC or no-DAC) paired with Ipamorelin provides sustained GH elevation, while the fragment handles targeted fat mobilization through its independent pathway.

Explore more combinations with our Peptide Stack Builder or browse the Top 10 Peptide Stacks guide.

Common Side Effects

Mild and generally transient (reported by a minority of users):

• Injection site redness, mild irritation, or minor swelling — the most commonly reported side effect
• Occasional headache — typically in the first few days of use
• Mild lethargy or fatigue — uncommon and usually temporary
• Slight lightheadedness — may be related to fasting rather than the peptide itself

What This Peptide Does NOT Cause

Unlike full growth hormone, HGH Fragment 176-191 does not produce:

• IGF-1 elevation
• Insulin resistance or blood glucose changes
• Water retention or edema
• Joint pain or carpal tunnel symptoms
• Increased hunger
• Cellular proliferation concerns (no mitogenic effect)

Contraindications

• Known allergy — to HGH Fragment 176-191, AOD-9604, or any component of the reconstituted preparation
• Pregnancy and breastfeeding — no safety data exists. Avoid entirely.
• Active cancer — while the fragment does not raise IGF-1 or promote proliferation through the GH receptor, the precautionary principle applies. Avoid use with active malignancies.
• Type 1 diabetes — not because the fragment affects blood sugar (it does not), but because the required fasting protocol may conflict with insulin-dependent glucose management. Consult your endocrinologist.
• Active eating disorders — the required fasting protocol and focus on fat loss may exacerbate disordered eating patterns.

Regulatory Status

• Not FDA-approved for human use — classified as a research peptide
• AOD-9604 (acetylated derivative) has received FDA GRAS status as a food substance, but this does not extend to the unmodified HGH Fragment 176-191
• WADA prohibited — banned by the World Anti-Doping Agency for competitive athletes
• Not a controlled substance in most jurisdictions, but regulations vary — check local laws